



Life Sciences

Life sciences leaders turn to WilmerHale for legal advice and business advantage. We provide incisive solutions to the business challenges facing biotechnology, pharmaceutical and medical device companies at all stages of growth. For over four decades, we have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, patent prosecution and portfolio development, licensing agreements and landmark collaborations, and have defended their innovations in critical patent litigation.



Counsel of Choice to Life Sciences Leaders...from Biotech to Medical Devices

Mergers and Acquisitions

 <i>acquisition by</i> Bristol-Myers Squibb \$430,000,000 October 2007	 <i>acquisition by</i> Amgen \$300,000,000 July 2007	 <i>acquisition of</i> APEX International Clinical Research Co. \$1,700,000,000 (New Taiwan Dollars) September 2007	 <i>acquisition by</i> Takeda Pharmaceutical \$8,800,000,000 May 2008	 <i>acquisition by</i> Roche \$140,000,000 May 2007
 <i>acquisition of</i> Targanta Therapeutics \$137,000,000 February 2009	 <i>acquisition by</i> Antisoma \$52,200,000 June 2008	 <i>merger with</i> Cornerstone BioPharma \$90,000,000 October 2008	 <i>acquisition of</i> ViaCell \$300,000,000 November 2007	

Public Offerings and Rule 144A Placements

 <i>Public Offering of</i> <i>Common Stock</i> \$96,153,000 Counsel to Underwriters April 2007	 <i>Public Offering of</i> <i>Common Stock</i> \$25,200,000 Counsel to Issuer December 2008	 <i>Public Offering of</i> <i>Common Stock</i> \$60,190,000 Counsel to Underwriters September 2007	 <i>Public Offering of</i> <i>Common Stock</i> \$30,895,900 Counsel to Underwriters January 2008	 <i>Public Offering of</i> <i>Common Stock</i> \$45,517,000 Counsel to Placement Agent February 2009
 <i>Public Offering of</i> <i>Common Stock</i> \$138,000,000 Counsel to Underwriters May 2007	 <i>Rule 144A Placement of</i> <i>2.50% Convertible Senior Notes due 2014</i> \$125,000,000 Counsel to Issuer June 2007	 <i>Public Offering of</i> <i>Common Stock</i> \$47,195,000 Counsel to Issuer February 2008	 <i>Public Offering of</i> <i>Common Stock</i> \$31,000,000 Counsel to Issuer April 2009	

Strategic Alliances and Collaborations

 <i>License from PDL BioPharma and Biogen Idec of anti-angiogenesis antibody for ophthalmic use</i>	 <i>License from Orphan Therapeutics of Lucassin® product for type 1 hepatorenal syndrome</i>	 <i>License to Hoffmann-La Roche to develop and commercialize therapeutics for inflammatory diseases</i>	 <i>Drug development collaboration with Purdue Pharma</i>	 <i>License to Takeda of RNAi platform technology</i>
 <i>License from XTL Biopharmaceuticals of compounds for the treatment of Hepatitis C Virus</i>	 <i>Collaboration with GSK to develop and commercialize microRNA therapeutics for inflammatory diseases</i>	 <i>Collaboration with Genzyme to develop and commercialize drug for genetic disorders</i>	 <i>License of rights to OcuSeal™ Liquid Ocular Bandage from HyperBranch</i>	


Venture Capital Financings

 \$41,800,000 <i>Third Round</i> April 2008	 \$11,000,000 <i>Second Round</i> December 2008	 \$33,000,000 <i>First Round</i> June 2008	 \$22,000,000 <i>Fourth Round</i> December 2008	 \$25,000,000 <i>Second Round</i> April 2008
 \$20,000,000 <i>Fourth Round</i> June 2008	 \$8,000,000 <i>First Round</i> December 2008	 \$25,000,000 <i>Second Round</i> May 2008	 \$32,000,000 <i>First Round</i> April 2008	



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

WilmerHale recognizes its corporate responsibility to environmental stewardship.



wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers regulated by the Solicitors' Regulation Authority. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. This material is for general informational purposes only and does not represent our legal advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all relevant legal developments. Prior results do not guarantee a similar outcome. © 2009 Wilmer Cutler Pickering Hale and Dorr LLP